Review




Structured Review

Sangon Biotech codon optimized nucleotide sequences for filc
Structural representations of <t>FilC</t> and PD-1 proteins (a) FilC – Structural model of the FilC protein, depicting its folded β -sheet arrangement. (b) PD-1 – Structural model of the PD-1 immune checkpoint receptor.
Codon Optimized Nucleotide Sequences For Filc, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+optimized+nucleotide+sequences+for+filc/pmc12450999-104-0-22?v=Sangon+Biotech
Average 86 stars, based on 1 article reviews
codon optimized nucleotide sequences for filc - by Bioz Stars, 2026-07
86/100 stars

Images

1) Product Images from "Novel immune checkpoint inhibitor FilC/PD-1 recombinant vaccinia virus inhibits hepatocellular carcinoma"

Article Title: Novel immune checkpoint inhibitor FilC/PD-1 recombinant vaccinia virus inhibits hepatocellular carcinoma

Journal: Frontiers in Medicine

doi: 10.3389/fmed.2025.1622209

Structural representations of FilC and PD-1 proteins (a) FilC – Structural model of the FilC protein, depicting its folded β -sheet arrangement. (b) PD-1 – Structural model of the PD-1 immune checkpoint receptor.
Figure Legend Snippet: Structural representations of FilC and PD-1 proteins (a) FilC – Structural model of the FilC protein, depicting its folded β -sheet arrangement. (b) PD-1 – Structural model of the PD-1 immune checkpoint receptor.

Techniques Used:

Structural quality assessment of FilC and PD-1 Models (a) FilC Model Validation: Various structural validation metrics, including Rfree, Clashscore, Ramachandran outliers, Sidechain outliers, and RSRZ outliers, are shown. The percentile ranks are indicated relative to all X-ray structures and those with similar resolution. (b) PD-1 Model Validation: Quality assessment of the PD-1 structural model based on Clashscore, Ramachandran outliers, and sidechain outliers. The percentile ranks are provided relative to all NMR structures.
Figure Legend Snippet: Structural quality assessment of FilC and PD-1 Models (a) FilC Model Validation: Various structural validation metrics, including Rfree, Clashscore, Ramachandran outliers, Sidechain outliers, and RSRZ outliers, are shown. The percentile ranks are indicated relative to all X-ray structures and those with similar resolution. (b) PD-1 Model Validation: Quality assessment of the PD-1 structural model based on Clashscore, Ramachandran outliers, and sidechain outliers. The percentile ranks are provided relative to all NMR structures.

Techniques Used: Biomarker Discovery

Brightfield and fluorescence microscopy images showing vaccinia virus–mediated transgene expression. (a) Brightfield image and (b) corresponding fluorescence image of HepG2 hepatocellular carcinoma cells 24 h post-infection with vv-PD-1/FilC at an MOI of X pfu/cell. Red fluorescence indicates reporter expression (e.g., mCherry) under the control of the viral promoter. Scale bars: 50 μm. (a) Brightfield image showing Hepa1-6 cell morphology 24 h after infection. (b) Corresponding fluorescence microscopy image illustrating strong transgene expression (red fluorescence), indicating efficient viral infection and gene delivery.
Figure Legend Snippet: Brightfield and fluorescence microscopy images showing vaccinia virus–mediated transgene expression. (a) Brightfield image and (b) corresponding fluorescence image of HepG2 hepatocellular carcinoma cells 24 h post-infection with vv-PD-1/FilC at an MOI of X pfu/cell. Red fluorescence indicates reporter expression (e.g., mCherry) under the control of the viral promoter. Scale bars: 50 μm. (a) Brightfield image showing Hepa1-6 cell morphology 24 h after infection. (b) Corresponding fluorescence microscopy image illustrating strong transgene expression (red fluorescence), indicating efficient viral infection and gene delivery.

Techniques Used: Fluorescence, Microscopy, Virus, Expressing, Infection, Control

Time-dependent viral replication kinetics of the FilC/PD-1 recombinant vaccinia virus in HCC and non-cancerous cell lines. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test; error bars represent SD ( n = 3); p < 0.01 compared to non-HCC cell lines at 48 h and 72 h.
Figure Legend Snippet: Time-dependent viral replication kinetics of the FilC/PD-1 recombinant vaccinia virus in HCC and non-cancerous cell lines. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test; error bars represent SD ( n = 3); p < 0.01 compared to non-HCC cell lines at 48 h and 72 h.

Techniques Used: Recombinant, Virus

Differential gene expression between FilC/PD-1–treated tumors and controls.
Figure Legend Snippet: Differential gene expression between FilC/PD-1–treated tumors and controls.

Techniques Used: Gene Expression



Similar Products

86
Sangon Biotech codon optimized nucleotide sequences for filc
Structural representations of <t>FilC</t> and PD-1 proteins (a) FilC – Structural model of the FilC protein, depicting its folded β -sheet arrangement. (b) PD-1 – Structural model of the PD-1 immune checkpoint receptor.
Codon Optimized Nucleotide Sequences For Filc, supplied by Sangon Biotech, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/codon+optimized+nucleotide+sequences+for+filc/pmc12450999-104-0-22?v=Sangon+Biotech
Average 86 stars, based on 1 article reviews
codon optimized nucleotide sequences for filc - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


Structural representations of FilC and PD-1 proteins (a) FilC – Structural model of the FilC protein, depicting its folded β -sheet arrangement. (b) PD-1 – Structural model of the PD-1 immune checkpoint receptor.

Journal: Frontiers in Medicine

Article Title: Novel immune checkpoint inhibitor FilC/PD-1 recombinant vaccinia virus inhibits hepatocellular carcinoma

doi: 10.3389/fmed.2025.1622209

Figure Lengend Snippet: Structural representations of FilC and PD-1 proteins (a) FilC – Structural model of the FilC protein, depicting its folded β -sheet arrangement. (b) PD-1 – Structural model of the PD-1 immune checkpoint receptor.

Article Snippet: Codon-optimized nucleotide sequences for FilC (GenBank accession no. OR123456 ) and the PD-1 inhibitor (GenBank accession no. OR123457 ) were synthesized by Sangon Biotech (Shanghai, China) and verified by Sanger sequencing prior to cloning.

Techniques:

Structural quality assessment of FilC and PD-1 Models (a) FilC Model Validation: Various structural validation metrics, including Rfree, Clashscore, Ramachandran outliers, Sidechain outliers, and RSRZ outliers, are shown. The percentile ranks are indicated relative to all X-ray structures and those with similar resolution. (b) PD-1 Model Validation: Quality assessment of the PD-1 structural model based on Clashscore, Ramachandran outliers, and sidechain outliers. The percentile ranks are provided relative to all NMR structures.

Journal: Frontiers in Medicine

Article Title: Novel immune checkpoint inhibitor FilC/PD-1 recombinant vaccinia virus inhibits hepatocellular carcinoma

doi: 10.3389/fmed.2025.1622209

Figure Lengend Snippet: Structural quality assessment of FilC and PD-1 Models (a) FilC Model Validation: Various structural validation metrics, including Rfree, Clashscore, Ramachandran outliers, Sidechain outliers, and RSRZ outliers, are shown. The percentile ranks are indicated relative to all X-ray structures and those with similar resolution. (b) PD-1 Model Validation: Quality assessment of the PD-1 structural model based on Clashscore, Ramachandran outliers, and sidechain outliers. The percentile ranks are provided relative to all NMR structures.

Article Snippet: Codon-optimized nucleotide sequences for FilC (GenBank accession no. OR123456 ) and the PD-1 inhibitor (GenBank accession no. OR123457 ) were synthesized by Sangon Biotech (Shanghai, China) and verified by Sanger sequencing prior to cloning.

Techniques: Biomarker Discovery

Brightfield and fluorescence microscopy images showing vaccinia virus–mediated transgene expression. (a) Brightfield image and (b) corresponding fluorescence image of HepG2 hepatocellular carcinoma cells 24 h post-infection with vv-PD-1/FilC at an MOI of X pfu/cell. Red fluorescence indicates reporter expression (e.g., mCherry) under the control of the viral promoter. Scale bars: 50 μm. (a) Brightfield image showing Hepa1-6 cell morphology 24 h after infection. (b) Corresponding fluorescence microscopy image illustrating strong transgene expression (red fluorescence), indicating efficient viral infection and gene delivery.

Journal: Frontiers in Medicine

Article Title: Novel immune checkpoint inhibitor FilC/PD-1 recombinant vaccinia virus inhibits hepatocellular carcinoma

doi: 10.3389/fmed.2025.1622209

Figure Lengend Snippet: Brightfield and fluorescence microscopy images showing vaccinia virus–mediated transgene expression. (a) Brightfield image and (b) corresponding fluorescence image of HepG2 hepatocellular carcinoma cells 24 h post-infection with vv-PD-1/FilC at an MOI of X pfu/cell. Red fluorescence indicates reporter expression (e.g., mCherry) under the control of the viral promoter. Scale bars: 50 μm. (a) Brightfield image showing Hepa1-6 cell morphology 24 h after infection. (b) Corresponding fluorescence microscopy image illustrating strong transgene expression (red fluorescence), indicating efficient viral infection and gene delivery.

Article Snippet: Codon-optimized nucleotide sequences for FilC (GenBank accession no. OR123456 ) and the PD-1 inhibitor (GenBank accession no. OR123457 ) were synthesized by Sangon Biotech (Shanghai, China) and verified by Sanger sequencing prior to cloning.

Techniques: Fluorescence, Microscopy, Virus, Expressing, Infection, Control

Time-dependent viral replication kinetics of the FilC/PD-1 recombinant vaccinia virus in HCC and non-cancerous cell lines. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test; error bars represent SD ( n = 3); p < 0.01 compared to non-HCC cell lines at 48 h and 72 h.

Journal: Frontiers in Medicine

Article Title: Novel immune checkpoint inhibitor FilC/PD-1 recombinant vaccinia virus inhibits hepatocellular carcinoma

doi: 10.3389/fmed.2025.1622209

Figure Lengend Snippet: Time-dependent viral replication kinetics of the FilC/PD-1 recombinant vaccinia virus in HCC and non-cancerous cell lines. Statistical analysis was performed using one-way ANOVA with Tukey’s post hoc test; error bars represent SD ( n = 3); p < 0.01 compared to non-HCC cell lines at 48 h and 72 h.

Article Snippet: Codon-optimized nucleotide sequences for FilC (GenBank accession no. OR123456 ) and the PD-1 inhibitor (GenBank accession no. OR123457 ) were synthesized by Sangon Biotech (Shanghai, China) and verified by Sanger sequencing prior to cloning.

Techniques: Recombinant, Virus

Differential gene expression between FilC/PD-1–treated tumors and controls.

Journal: Frontiers in Medicine

Article Title: Novel immune checkpoint inhibitor FilC/PD-1 recombinant vaccinia virus inhibits hepatocellular carcinoma

doi: 10.3389/fmed.2025.1622209

Figure Lengend Snippet: Differential gene expression between FilC/PD-1–treated tumors and controls.

Article Snippet: Codon-optimized nucleotide sequences for FilC (GenBank accession no. OR123456 ) and the PD-1 inhibitor (GenBank accession no. OR123457 ) were synthesized by Sangon Biotech (Shanghai, China) and verified by Sanger sequencing prior to cloning.

Techniques: Gene Expression